background
noncyst
fibrosi
bronchiectasi
chronic
structur
lung
condit
cours
recurr
infecti
exacerb
lead
frequent
antibiot
treatment
make
popul
suscept
acquir
pathogen
antibiot
resist
aim
investig
risk
factor
associ
isol
multidrugresist
pathogen
bronchiectasi
exacerb
method
prospect
observ
studi
conduct
two
tertiarycar
hospit
enrol
patient
first
exacerb
appear
multidrugresist
determin
accord
european
centr
diseas
prevent
control
classif
result
two
hundr
thirti
three
exacerb
includ
microorgan
isol
episod
multidrugresist
pathogen
found
episod
pseudomona
aeruginosa
methicillinresist
staphylococcu
aureu
extend
spectrum
betalactamas
enterobacteriacea
frequent
exacerb
requir
hospit
vs
p
three
independ
multidrugresist
risk
factor
found
chronic
renal
diseas
odd
ratio
ci
hospit
previou
year
ci
prior
multidrugresist
isol
ci
proport
multidrugresist
exacerb
follow
patient
without
risk
factor
factor
risk
factor
conclus
hospit
previou
year
chronic
renal
diseas
prior
multidrugresist
isol
risk
factor
identif
multidrugresist
pathogen
exacerb
inform
may
assist
clinician
choos
empir
antibiot
daili
clinic
practic
multidrugresist
mdr
pathogen
worldwid
health
threat
clinic
neg
consequ
inadequ
recogn
treat
noncyst
fibrosi
bronchiectasi
chronic
structur
lung
condit
facilit
chronic
colon
microorgan
cours
frequent
exacerb
recurr
infect
mean
patient
receiv
numer
cours
broadspectrum
antibiot
make
like
acquir
mdr
pathogen
main
pathogen
involv
chronic
colon
acut
exacerb
haemophilu
influenza
streptococcu
pneumonia
pseudomona
aeruginosa
lesser
extent
enterobacteriacea
incid
spread
mdr
microorgan
among
patient
worrisom
antibiot
arsen
scarc
threaten
potenti
mdr
pathogen
respiratori
patient
includ
p
aeruginosa
extendedspectrum
betalactamas
esbl
enterobacteriacea
pathogen
difficult
treat
requir
differ
antibiot
regimen
usual
recommend
guidelin
knowledg
prospect
studi
aim
identifi
independ
risk
factor
mdr
pathogen
exacerb
hypothes
mdr
exacerb
depend
patient
characterist
includ
usual
treatment
prior
health
contact
knowledg
factor
may
use
reduc
inappropri
antibiot
treatment
aim
studi
investig
risk
factor
associ
isol
multidrug
resist
microorgan
bronchiectasi
exacerb
clinic
impact
outcom
conduct
prospect
observ
studi
adult
patient
bronchiectasi
attend
special
clinic
two
tertiari
care
univers
hospit
period
specif
special
clinic
patient
refer
primari
care
hospit
specialti
medic
facil
confirm
diagnosi
bronchiectasi
computer
tomographi
scan
lung
along
compat
symptom
aetiolog
bronchiectasi
investig
accord
spanish
guidelin
previou
studi
recruit
local
committe
approv
studi
patient
gave
written
inform
consent
biomed
research
ethic
committe
hospit
la
fe
patient
enrol
studi
present
first
exacerb
sign
inform
consent
requir
new
antibiot
treatment
hospit
admiss
subsequ
exacerb
everi
patient
includ
exclus
criteria
sever
immunosuppress
solidorgan
bonemarrow
transplant
hivaid
receiv
chemotherapi
immunosuppress
drug
mg
prednisoneequival
per
day
week
b
activ
tuberculosi
c
cystic
fibrosi
cf
pulmonari
interstiti
diseas
e
hospit
preced
day
data
collect
demograph
diagnosi
smoke
alcohol
abus
flu
vaccin
statu
comorbid
also
record
diabet
copd
asthma
heart
diseas
prior
tuberculosi
renal
liver
cerebrovascular
diseas
ageadjust
charlson
score
data
relat
prior
microorgan
isol
number
exacerb
previou
year
bronchiectasi
sever
score
bsi
face
also
record
chronic
concomit
medic
includ
bronchodil
corticosteroid
theophyllin
inhalednebul
antibiot
proton
pump
inhibitor
longterm
oxygen
therapi
mucolyt
drug
histori
prior
exacerb
hospit
previou
year
also
detail
definit
exacerb
accord
spanish
guidelin
follow
acut
chang
sputum
characterist
increas
volum
chang
viscos
purul
without
increas
dyspnea
rule
caus
along
requir
new
antibiot
treatment
prescrib
specif
clinic
unschedul
admiss
hospit
includ
also
exacerb
new
chest
xray
infiltr
diagnos
pneumonia
attend
physician
made
decis
admit
hospit
exacerb
episod
data
collect
chang
initi
antibiot
complic
invas
noninvas
mechan
ventil
mortal
length
hospit
stay
record
hospit
patient
new
exacerb
year
followup
inappropri
antibiot
treatment
consid
pathogen
suscept
prescrib
antibiot
respect
vitro
suscept
test
patient
follow
visit
special
clinic
day
day
year
discharg
microbiolog
diagnosi
perform
follow
test
sputum
patient
urin
antigen
test
pneumonia
l
pneumophila
two
blood
sampl
nasopharyng
swab
influenza
b
parainfluenza
syncyti
respiratori
viru
adenoviru
sputum
bronchoalveolar
lavag
process
gram
ziehlneelsen
stain
cultur
bacteri
fungal
mycobacteri
pathogen
sputum
sampl
consid
accept
leukocyt
fewer
squamou
cell
per
lowpow
microscop
field
invas
sampl
obtain
request
attend
physician
microorgan
identif
consid
posit
previou
public
briefli
bacteri
identif
achiev
mean
malditof
ms
biomerieux
marci
letoil
franc
antimicrobi
suscept
test
kirbybau
disk
diffus
techniqu
mullerhinton
sheep
blood
agar
depend
microorgan
growth
requir
etest
inhous
pcr
use
assess
unexpect
resist
pattern
concept
multidrug
resist
pathogen
mdr
mdr
pathogen
classifi
accord
european
centr
diseas
prevent
control
p
aeruginosa
consid
mdr
non
suscept
least
agent
antimicrobi
categori
mrsa
defin
aureu
resist
oxacillin
correspond
minimum
inhibitori
concentr
mic
mcgml
enterobacteriacea
defin
esbl
present
resist
antibiot
includ
penicillin
cephalosporin
aztreonam
statist
analys
perform
use
spss
softwar
program
qualit
variabl
compar
use
test
quantit
variabl
analyz
use
anova
test
kruskalw
test
valu
p
consid
statist
signific
length
stay
dichotom
short
day
long
stay
face
bsi
dichotom
sever
point
respect
sever
logist
regress
analys
perform
predict
mdr
pathogen
depend
variabl
independ
variabl
includ
found
univari
analysi
p
variabl
highli
correl
exclud
analysi
subset
patient
nonmdr
pathogen
use
refer
group
second
logist
regress
analysi
also
perform
use
refer
group
patient
nonmdr
pathogen
patient
without
etiolog
diagnosi
hosmer
lemeshow
goodnessoffit
test
use
evalu
adequaci
model
area
receiveroper
characterist
roc
curv
also
calcul
recruit
patient
one
exacerb
microbi
isol
found
fig
characterist
patient
diagnosi
previou
microorgan
isol
number
exacerb
number
prior
antibiot
treatment
usual
concomit
medic
sever
score
describ
tabl
frequent
pathogen
found
exacerb
describ
tabl
mdr
pathogen
isol
exacerb
found
microorgan
repres
microorgan
isol
mdr
pseudomona
aeruginosa
methicillinresist
staphylococcu
aureu
extendedspectrum
betalactamaseproduc
enterobacteriacea
proteu
mirabili
serratia
marcescen
bacteria
achromobact
xylosoxidan
stenotrophomona
maltophilia
brevundimona
diminuta
mdr
escherichia
coli
esbl
haemophilu
influenza
esbl
mdr
mycobacterium
abscessu
patient
requir
admiss
like
grow
mdr
organ
requir
admiss
vs
fig
antibiot
initi
prescrib
exacerb
chang
patient
occur
frequent
mdr
pathogen
without
reach
statist
signific
vs
tabl
depict
outcom
exacerb
regard
isol
mdr
pathogen
patient
without
isol
includ
characterist
patient
comorbid
condit
usual
treatment
score
regard
presenc
absenc
mdr
shown
tabl
exacerb
record
patient
hospit
admit
mdr
pathogen
frequent
encount
patient
chronic
condit
higher
face
bsi
score
differ
found
concern
usual
prior
treatment
patient
prior
hospit
show
significantli
frequent
incid
mdr
three
independ
predictor
mdr
exacerb
identifi
area
roc
curv
model
ci
tabl
second
model
use
refer
group
patient
nonmdr
pathogen
without
etiolog
diagnosi
risk
factor
remain
independ
associ
mdr
bacteria
presenc
mdr
exacerb
regard
number
recogn
risk
factor
found
shown
fig
risk
factor
identifi
patient
probabl
mdr
patient
probabl
increas
risk
factor
risk
factor
present
total
cohort
notabl
find
studi
follow
mdr
pathogen
frequent
isol
exacerb
higher
proport
among
hospit
patient
princip
mdr
microorgan
pseudomona
mrsa
esbl
enterobacteriacea
independ
mdr
risk
factor
prior
mdr
isol
hospit
previou
year
chronic
renal
diseas
due
structur
chang
perman
dilat
airway
bronchiectasi
cours
recurr
infect
exacerb
pathogen
involv
depend
sever
aspect
lung
function
advanc
phase
diseas
patient
comorbid
howev
littl
known
regard
frequenc
factor
associ
isol
mdr
exacerb
found
exacerb
mdr
pathogen
isol
frequent
pseudomona
mrsa
esbl
enterobacteriacea
evalu
resist
use
convent
method
usual
perform
daili
routin
nt
perform
autom
method
clonal
analysi
resist
percentag
spectrum
mdr
similar
nosocomi
communityacquir
infect
line
current
approach
problemat
pathogen
base
host
characterist
prior
treatment
slightli
higher
report
mcdonnel
et
al
fact
mdr
exacerb
occur
elderli
patient
higher
proport
comorbid
condit
indic
associ
debilit
diseas
requir
p
valu
test
perform
categor
data
mannwhitney
u
test
perform
continu
data
contact
health
resourc
result
show
use
prior
inhal
antibiot
longterm
oxygen
therapi
greater
patient
mdr
pathogen
interestingli
differ
found
regard
use
bronchodil
inhal
corticosteroid
meterski
et
al
report
healthcar
associ
pneumonia
inhal
corticosteroid
associ
pseudomona
etiolog
although
found
associ
resist
spectrum
microorgan
identifi
whether
treat
outpati
hospit
similar
except
fact
mdr
bare
encount
outpati
fact
mdr
exacerb
frequent
admit
clinic
relev
exacerb
requir
hospit
report
associ
increas
mortal
studi
found
three
independ
mdr
risk
factor
renal
diseas
prior
mdr
isol
hospit
previou
year
chronic
renal
diseas
recogn
mdr
risk
factor
report
pneumonia
studi
shindo
et
al
identifi
independ
mdr
risk
factor
regardless
whether
patient
healthcar
associ
communityacquir
pneumonia
suggest
risk
factor
reli
host
factor
set
infect
prior
hospit
fairli
wide
recogn
independ
mdr
risk
factor
specif
mrsa
enterobacteriacea
mainli
relat
exposur
iiiiv
gener
cephalosporin
broadspectrum
penicillin
prior
mdr
isol
independ
associ
higher
risk
mdr
exacerb
cohort
approxim
patient
chronic
pseudomona
infect
reflect
sever
patient
seen
specif
clinic
prior
mdr
colon
recogn
risk
factor
mrsa
pseudomona
copd
patient
found
patient
mdr
exacerb
prior
isol
microorgan
proport
mdr
exacerb
higher
among
patient
higher
face
bsi
score
expect
advanc
diseas
proport
exacerb
hospit
almost
mdr
exacerb
occur
patient
higher
punctuat
prognost
scale
face
bsi
wherea
mdr
mild
scale
lower
respect
howev
enter
model
independ
factor
scale
remain
independ
associ
multidrug
resist
regard
antimicrobi
suscept
mdr
exacerb
receiv
less
appropri
treatment
nonmdr
thu
also
requir
chang
antibiot
regimen
although
without
statist
differ
fact
choic
initi
treatment
microbiolog
suitabl
case
probabl
physician
took
consider
prior
mdr
colon
polici
support
find
current
factor
consid
antibiot
select
includ
extent
diseas
sever
local
resist
pattern
prior
cultur
result
practic
conclus
extendedspectrum
antibiot
mdr
could
withdrawn
patient
risk
factor
indic
risk
factor
present
risk
factor
present
extendedspectrum
antibiot
may
indic
mdr
pathogen
rule
microbiolog
workup
therefor
implement
nevertheless
recommend
need
valid
differ
popul
subset
knowledg
local
resist
rate
colon
rate
consid
polici
may
contribut
contain
broadspectrum
coverag
mdr
unnecessari
episod
strategi
may
contribut
curb
futur
emerg
resist
microorgan
popul
patient
mdr
exacerb
requir
hospit
greater
use
antibiot
although
without
longer
hospit
stay
gener
mdr
infect
associ
higher
number
day
hospit
higher
antibiot
requir
hospit
use
health
resourc
attend
higher
cost
may
eventu
neg
impact
prognosi
nevertheless
consid
oneyear
followup
could
insuffici
evalu
potenti
clinic
impact
mdr
exacerb
probabl
aim
subsequ
exacerb
assess
pathogen
identif
reli
mainli
convent
microbiolog
test
invas
respiratori
sampl
indic
requir
attend
physician
real
clinic
scenario
common
clinic
hospit
set
quantit
bacteriolog
measur
coloni
count
quantifi
sputum
due
number
patient
cohort
secondari
analysi
separ
specif
risk
factor
microorgan
undertaken
mild
episod
exacerb
treat
primari
care
evalu
specif
clinic
includ
first
studi
aim
identifi
risk
factor
mdr
exacerb
potenti
impact
clinic
decis
antibiot
choic
present
bt
guidelin
suggest
combin
therapi
rather
singledrug
antibiot
therapi
resist
strain
p
aeruginosa
isol
find
could
use
avoid
unnecessari
broadspectrum
antibiot
patient
without
mdr
risk
factor
find
identifi
three
independ
risk
factorshospit
previou
year
chronic
renal
diseas
prior
multidrugresist
isolationfor
identif
multidrugresist
pathogen
exacerb
inform
may
use
clinician
guid
initi
antibiot
therapi
exacerb
valid
differ
cohort
includ
distinct
phenotyp
larger
followup
period
perform
mdr
risk
predict
exacerb
new
field
requir
valid
clinic
decisionmak
select
initi
appropri
antibiot
safe
avoid
antimdr
coverag
